About anavex life sciences corp - AVXL
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
AVXL At a Glance
Anavex Life Sciences Corp.
630 5th Avenue
New York, New York 10111
| Phone | 1-844-689-3939 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -46,377,000.00 | |
| Sector | Health Technology | Employees | 34 | |
| Fiscal Year-end | 09 / 2026 | |||
| View SEC Filings |
AVXL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 8.131 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -12.77 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
AVXL Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,364,029.412 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
AVXL Liquidity
| Current Ratio | 11.605 |
| Quick Ratio | 11.605 |
| Cash Ratio | 11.466 |
AVXL Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -38.747 |
| Return on Equity | -43.115 |
| Return on Total Capital | -48.885 |
| Return on Invested Capital | -43.115 |
AVXL Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |